MRK241227P100000
- 0.72
- -0.46-38.98%
Merck & Co Newsroom
BMO Capital has lowered the Target Price for Merck to 105 dollars.
BMO Capital Downgrades Merck & Co(MRK.US) to Hold Rating, Cuts Target Price to $105
Merck & Co Analyst Ratings
BMO Capital Downgrades Merck & Co to Market Perform, Lowers Price Target to $105
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $123
BMO Capital Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $136
Bernstein Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $110
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $123
Bernstein Keeps Their Hold Rating on Merck & Company (MRK)
BofA Securities Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $121
BofA Securities Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $121
Merck & Co Analyst Ratings
B of A Securities Reinstates Buy on Merck & Co, Announces $121 Price Target
Berenberg Bank Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $125
HSBC Upgrades Merck & Co(MRK.US) to Buy Rating, Raises Target Price to $130
Bernstein Maintains Merck & Co(MRK.US) With Hold Rating, Cuts Target Price to $110
Bernstein Trims Price Target on Merck to $110 From $115
Jefferies Maintains Merck & Co(MRK.US) With Buy Rating, Raises Target Price to $150
Jefferies Reaffirms Their Buy Rating on Merck & Company (MRK)
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $123